drugset / Trial / NCT02813486

Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine

NCT02813486

Phase 1/2 Unknown 220 enrolled Green Cross Corporation
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate safety of GC3111 and to describe immunogenicity of a single dose of GC3111 versus Boostrix® vaccine among healthy adults in 19 to \<65 years of age.

Timeline

Start
2016-06
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Boostrix Vaccine 0.5 ml Intramuscular
Subject GC3111 Vaccine 0.5 ml Intramuscular